Recommendation from Software & IT Services and Healthcare Sector
Ratin Biswass / 20 Feb 2025/ Categories: DSIJ_Magazine_Web, DSIJMagazine_App, Hot Chips, Hot Chips, Recommendations
The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.
The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations. [EasyDNNnews:PaidContentStart]
TECH MAHINDRA LTD
CMP - ₹1,704.50
BSE CODE 532755
Volume 34,216
Face Value ₹5
Target ₹1,841 - ₹1,875
Stoploss ₹1,585 (CLS)
Tech Mahindra, a leading Indian IT services company and part of the Mahindra Group, provides a comprehensive range of IT services, including IT-enabled services, application development and maintenance, consulting, and enterprise business solutions. Despite a modest 1.4 per cent revenue growth, rising from ₹13,101 crore in Q3FY24 to ₹13,285 crore in Q3FY25, net profit soared around 90 per cent year-on-year, significantly outperforming leading IT majors. This strong bottom-line expansion underscores the company's resilience and operational efficiency amid a challenging industry landscape. Shares of the company witnessed a surge in buying interest following the announcement that the Board of Directors approved the merger plan of Tech Mahindra Cerium Systems Inc., a wholly-owned subsidiary, with Tech Mahindra (Americas) Inc., a key material subsidiary. The move signals strategic consolidation to enhance operational synergies. Hence, considering the upside potential, we recommend BUY.
Narayana Hrudayalaya Ltd
CMP - ₹1,369.85
BSE CODE 539551
Volume 17,775
Face Value ₹10
Target ₹1,479 - ₹1,507
Stoploss ₹1,274 (CLS)
Narayana Hrudayalaya, now Narayana Health, is a leading Indian healthcare provider with a network of multispecialty and super-speciality hospitals across multiple locations. It specialises in cardiac care, oncology, neurology, and organ transplants. The company emphasises cost-effective treatments, advanced medical technology, and accessible healthcare. When assessing the financial performance, there was a notable revenue growth of around 14 per cent, surging from ₹1,204 crore in Q3FY24 to a total revenue of ₹1,367 crore in Q3FY25. The net profit, on the other hand, experienced a slight year-on-year gain. The company has introduced a new phase of its 'Apno Ki Fikr' campaign, highlighting critical specialities and underscoring the importance of timely medical intervention.It aims to reassure families that expert healthcare is readily available when they need it most. From a technical perspective, the stock exhibits strong upside potential. Therefore, we recommend BUY.
[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]
To read the entire article, you must be a DSIJ magazine subscriber.
[EasyDNNnews:UnPaidContentEnd]